New study examines pain and adherence in patients switching to concentrated adalimumab
Symptom relief
Completed
This study involved 324 adults with conditions like Crohn's disease, arthritis, or psoriasis who switched from a standard to a higher-concentration form of adalimumab (AVT-02). Researchers measured injection site pain and how well patients stuck with their treatment over 180 days…
Sponsor: Jamp Pharma Corporation • Aim: Symptom relief
Last updated Jun 17, 2026 01:30 UTC